CONMED Corp 2026年季度报告

Washington, D.C. 20549 FORM 10-Q Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or anemerging growth company.See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growthcompany" in Rule 12b-2 of the Exchange Act (Check one). Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐ Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of shares outstanding of registrant's common stock, as of July27, 2026 is 29,951,248 shares. Item Number Item 1.Financial Statements (unaudited)– Consolidated Condensed Statements of Comprehensive Income for the three and six months ended June30, 2026 and 20251– Consolidated Condensed Balance Sheets as of June 30, 2026 and December 31, 20252– Consolidated Condensed Statements of Shareholders' Equity for the three and six months ended June30, 2026 and 20253– Consolidated Condensed Statements of Cash Flows for thesix months ended June 30, 2026 and 20254– Notes to Consolidated Condensed Financial Statements5Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations20Item 3.Quantitative and Qualitative Disclosures About Market Risk27Item 4.Controls and Procedures28PART II OTHER INFORMATIONItem 1.Legal Proceedings28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds28Item 5.Other Information29Item 6.Exhibits30Signatures31 PART IFINANCIAL INFORMATION CONMED CORPORATIONCONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME(Unaudited, in thousands except per share amounts) CONMED CORPORATIONCONSOLIDATED CONDENSED BALANCE SHEETS(Unaudited, in thousands except share and per share amounts) CONMED CORPORATIONCONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) CONMED CORPORATIONNOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS(Unaudited, in thousands except per share amounts) Note 1 -Operations CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides devicesand equipment for surgical procedures.The Company’s products are used by surgeons and other healthcare professionals in a varietyof specialties including orthopedics, general surgery, gynecology, and thoracic surgery. During the quarter ended March31, 2026, the Company sold certain assets related to our gastroenterology product offeringsfor $7.0 million and we recorded a gain of $3.9 million on this asset sale to selling and administrative expense. During the quarterended June30, 2026, we recorded an additional gain of $1.9 million to selling and administrative expense. During the quarter ended June30, 2026, the Company completed the sale of additional assets related to our gastroenterologyproduct offerings for $14.0 million. This sale was accounted for as a sale of a business which resulted in a $4.4 million loss as furtherdescribed in Note 9. Note 2 - Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generallyaccepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of RegulationS-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles forannual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion ofmanagement, necessary to fairly state the results for the periods presented. The consolidated condensed financial statements hereinconsist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results forthe periods ended June30, 2026 are not necessarily indicative of the results that may be expected for the year ending December31,2026. The consolidated condensed